MDS 2023 | BMT CTN 1102: pre-transplantation QoL measures improve prognostication in HR-MDS
Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Italy, discusses recent patient-reported outcome (PRO) and quality of life (QoL) results from the BMT CTN 1102 trial (NCT02016781). This trial evaluated the benefits of allogeneic hematopoietic stem cell transplantation (alloHSCT) versus non-transplantation therapies in older patients with high-risk myelodysplastic syndromes (HR-MDS). Dr Efficace explains that pre-transplant QoL data provided independent prognostic information for survival in this patient group. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy/Advisory Board: Abbvie, Syros, Incyte, Janssen
